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Abstract. Commonly in biomedical research, studies collect data in which an outcome measure contains
informative excess zeros; for example when observing the burden of neuritic plaques in brain pathology
studies, those who show none contribute to our understanding of neurodegenerative disease. The outcome
may be characterized by a mixture distribution with one component being the ‘structural zero’ and the
other component being a Poisson distribution. We propose a novel variance components score test of genetic
association between a set of genetic markers and a zero-inflated count outcome from a mixture distribution.
This test shares advantageous properties with SNP-set tests which have been previously devised for standard
continuous or binary outcomes, such as the Sequence Kernel Association Test (SKAT). In particular, our
method has superior statistical power compared to competing methods, especially when there is correlation
within the group of markers, and when the SNPs are associated with both the mixing proportion and
the rate of the Poisson distribution. We apply the method to Alzheimer’s data from the Rush University
Religious Orders Study and Memory and Aging Project (ROSMAP), where as proof of principle we find
highly significant associations with the APOE gene, in both the ‘structural zero’ and ‘count’ parameters,
when applied to a zero-inflated neuritic plaques count outcome.
Key words: zero-inflated Poisson; SNP sets; variance components score tests; kernel machines; omnibus
test of multiple parameters
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1. Introduction
It is common to encounter data that would be appropriate to model with a so-called zero-inflated dis-
tribution, where some proportion of subjects obtain a zero outcome while the remainder obtain a positive
outcome from some standard distribution. In analyzing such data in order to discover associations with
genetic markers, it is important to use statistical tests that are adapted to this setting, both in order to
appropriately control type I error and maximize power. This can present a challenge for naive approaches.
For example, dichotomizing the data or disregarding the zeros is obviously problematic because each of these
approaches results in data loss, ignoring information that can contribute to our understanding. Another sim-
ple approach uses the available zero-inflated data, but fails to account for zero-inflation. Namely, one could
perform a multivariate Wald test using the Huber-White robust variance estimator within the usual Poisson
regression. However, in our simulations we find that this last approach can fail to preserve type I error.
In this paper we propose an association testing procedure, modeling the outcome via zero-inflated Poisson
(ZIP) regression (Lambert, 1992), a simple yet flexible model that can be used to infer about the underlying
mixture of two subgroups: (i) the ‘structual zero’ group representing a ‘healthy’ or unaffected population;
and (ii) the ‘susceptible group’ with varying degrees of severity captured by a Poisson distribution.
We aim to develop testing procedures that can effectively assess the overall association between a set of
genetic markers and a zero-inflated count outcome. SNP-set analyses have been advocated as having several
advantages over standard single-SNP analyses including better reproducibility, power and interpretability
(Liu et al., 2007, 2008; Wu et al., 2010). For example, with gene-level SNP sets, several SNPs may affect
transcription levels of a given protein. Individual SNP effects may combine additively or may involve more
complex interactions. Marginal testing of individual SNPs may miss important signals, first due to low
power from inability to combine weak effects across multiple SNPs, and second due to poor model fit from
inability to model interactions or other complex effects. Marginal testing also suffers from additional multiple-
comparisons. Variance components score tests for semi-parametric kernel regression been previously shown
to outperform standard multivariate tests with p degrees of freedom in these of these respects, within the
continuous, binary, and time-to-event outcome settings (Wu et al., 2010, 2011; Lin et al., 2011; Shen and
Cai, 2016).
By modeling the zero-inflated count outcome via ZIP or zero-inflated negative binomial (ZINB) (Greene,
1994), one may form Wald tests to assess the overall association between a SNP set and the outcome.
However, such Wald tests have limited power when the SNPs are in high linkage disequilibrium (LD) with
each other. Furthermore, these simple Wald test procedures cannot easily accommodate non-linear effects
and are sensitive to model mis-specification. To overcome these challenges, we propose in this paper a
variance component test via the ZIP framework to detect signals from both the genetic effect on the mixing
proportion and on the Poisson rate. (Since it is not our focus here, we refer the reader to references in the
literature, e.g. (Ridout et al., 2001) where various tests have been proposed for detecting when a data set is
zero-inflated, or if it is zero-inflated, whether there is overdispersion in the Poisson model.)
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The rest of the article is organized as follows. In Section 2, we introduce the ZIP kernel-machine setting
and we present the score test and procedures for approximating the null distribution of the proposed test.
Simulation results are presented in Section 3 and the proposed procedures are illustrated by assessing the
association of a zero-inflated neuritic plaques count phenotype with gene-level SNP-sets in the ROSMAP
cohort. We conclude with a discussion.
2. Methods
2.1. Description of Data. Suppose we have genetic data for n subjects with a set of p SNPs and q
covariates. Let Yi, Gi = (Gi1, Gi2, .., Gip), Xi = (Xi1, Xi2, .., Xiq), indicate respectively the the ith subject’s
outcome, genotypes, and covariates. We assume that D = {Di = (Yi,G>i ,X>i )>, i = 1, ..., n} are independent
and identically distributed random vectors. Covariates might include age, gender, and, to control population
stratification, top principal components of the genetic covariance matrix. For our examples, genotypes
Gij = 0, 1, or 2 represent the number of minor alleles at a given locus under the assumption of an additive
genetic model. However, one can recode genotypes if dominant or recessive models are desirable. The
count outcome phenotype Yi is assumed to follow a ZIP model consisting of two components: 1) structural
zeros with probability 1 − pii, , and 2) a Poisson(λi) distribution with probability pii. (Note that the
parameterization of pii is nonstandard, but is here chosen so the direction of effect in the pii regression and
the λi regression agree qualitatively in sign.)
Our goal is to devise a testing procedure to assess whether Gi plays a role in either λi or pii. To this end,
we note that the ZIP likelihood takes the form
(2.1)
n∏
i=1
L(pii, λi|Di) =
n∏
i=1
{(1− pii)I(Yi = 0) + pii(e−λiλYii /Yi!)}
We further parameterize the ZIP model in semi-parametric fashion, where we assume the effect of Gi on Yi
is fully captured by the functions hpi(Gi) and hλ(Gi):
(2.2) logit(pii) = X>i βpi + hpi(Gi)
(2.3) log(λi) = X>i βλ + hλ(Gi)
Hence in our genetic testing paradigm we are interested in testing H0 : hλ(·) = hpi(·) = 0. If hpi(·) 6= 0, we
say that genotypes are associated with the structural zeros, if hλ(·) 6= 0, we say that genotypes are associated
with the mean of the Poisson component of the mixture. For the purposes of this paper, we assume that
hpi(Gi) = Ψ(Gi)
>γpi and hλ(Gi) = Ψ(Gi)
>γλ, for a given set of basis functions Ψ(·). In practice, Ψ(·) can
be set to identity, leading to a testing of linear effects or pre-specified using non-linear basis functions. An
alternative strategy to choose Ψ(·) is through kernel principal component analysis as suggested in Shen and
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Cai (2016). More specifically, for a given kernel function and the observed data on Gi, one may estimate the
basis functions associated with the corresponding reproducible kernel Hilbert space by constructing the kernel
matrix for the observed sample and obtaining the leading eigenvectors as Ψ(Gi). With a given Ψ(·), testing
the hypotheses of H0 is then equivalent to testing H0 :γpi = (γpi1, ..., γpiK)> =γλ = (γλ1, ..., γλK)> = 0.
2.2. Test statistic. To overcome the potential high dimensionality in Ψ(Gi) and leverage the correlation
among the SNPs, we propose to impose a working assumption that γι1, ..., γιK are independent and identically
distributed random variables with mean 0 and variance τ2ι , for ι ∈ {pi, λ}; and derive a score test for the
variance components τpi and τλ. Under this set-up, testing H0 is now translated into testing H0 : τpi = τλ =
0. The variance component score test paradigm built on the random effects working assumptions attains
statistical efficiency gain essentially by taking advantage of the correlation within G to reduce the degrees of
freedom. These random effects working assumptions are merely a convenience in developing the test statistic;
they are not required for the validity of the test. By using a score test we also have the convenience of only
needing to fit the null model where logit(pi0,i) = X>i β0,pi, and log(λ0,i) = X>i β0,λ, so that the model fit
can be accomplished with standard maximum-likelihood fixed-effects ZIP regression software. This means
it is computationally feasible to test a large number of SNP sets, even if, as with our method, resampling is
necessary to obtain the distribution of the test statistic.
To form the test statistic, we write γιk = τιειk so that E(ειk) = 0, and V ar(ειk) = 1, and all covariances
Cov(ειk, ει′k′) = 0 when ι 6= ι′ or k 6= k′. Then for ι ∈ {pi, λ}, we define the score test statistic associated
with τι as
Qˆι = Eε
{ ∂ log∏ni=1 L(pii, λi|Di)
∂τι
∣∣∣∣
τpi=τλ=0
}2∣∣∣∣∣∣D
 = nSˆ>ι Sˆι = ∥∥∥√nSˆι∥∥∥2
2
, where Sˆι = n−1
n∑
i=1
rˆι,iΨ(Gi).
Here, rˆpi,i and rˆλ,i can be thought of as a covariate-adjusted scalar residual that is typical of a score statistic.
Explicitly,
(2.4) rˆpi,i ≡ rpi(Yi,X>i β̂0,pi,X>i β̂0,λ) ≡ I(Yi = 0)
pˆi0,i(1− pˆi0,i)(1− exp(−λˆ0,i))
1− pˆi0,i(1− exp(−λˆ0,i))
− I(Yi > 0)(1− pˆi0,i)
and
(2.5) rˆλ,i ≡ rλ(Yi,X>i β̂0,pi,X>i β̂0,λ) ≡ I(Yi = 0)
pˆi0,iλˆ0,iexp(−λˆ0,i)
1− pˆi0,i(1− exp(−λˆ0,i))
− I(Yi > 0)(Yi − λˆ0,i),
where logitpˆi0,i = X>i β̂0,pi, log λˆ0,i = X>i β̂0,λ, and β̂0 = (β̂
>
0,pi, β̂
>
0,λ)
> is the maximum likelihood estimator of
the covariate effects β0 = (β
>
0,pi,β
>
0,λ)
>underH0. Note that Ê(Yi) = pˆi0,iλˆi, ̂P (Yi > 0) = pˆi0,i(1−exp(−λˆ0,i)),
so that rˆpi,i = I(Yi = 0)(1 − pˆi0,i) ̂P (Yi>0)̂P (Yi=0) − I(Yi > 0)(1 − pˆi0,i) and rˆλ,i = I(Yi = 0)
Ê(Yi)exp(−λˆ0,i)
̂P (Yi=0)
− I(Yi >
0)(Yi − λˆ0,i). For ι ∈ {pi, λ}, the statistic Qˆι can be interpreted as the L2 norm of an empirical covariance
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between the residuals {rˆι,i} estimated under the null of no genetic effect and the transformed genotypes
{Ψ(Gi)}.
In Appendix 1, we show that under H0, the covariances Sˆpi and Sˆλ converges to zero in probability
and
√
nSˆ ≡ √n(Sˆ>pi , Sˆ>λ )> converges in distribution to a multivariate normal with covariance matrix Σ = Σpi,pi Σpi,λ
Σ>pi,λ Σλ,λ
, where Σι,ι′ = cov(Φι,i,Φι′,i), Φι,i = rι,iΨ(Gi) + ρι,piI−1pi Upi,i + ρι,λI−1λ Uλ,i, Uι,i and Iι
are the respective score and information matrix for βι, ρι,pi = E
[
r˙2ι(Yi,X
>
i β0,pi,X
>
i β0,λ)Ψ(Gi)X
>
i
]
, ρι,λ =
E
[
r˙3ι(Yi,X
>
i β0,pi,X
>
i β0,λ)Ψ(Gi)X
>
i
]
, and r˙kι = ∂rι(x1, x2, x3)/∂xk. It follows (see Appendix 1) that Qˆι
converges in distribution to a mixture of χ21 distributions with mixing parameters being the eigenvalues of
Σι,ι, for ι ∈ pi, λ.
To form an omnibus test for H0 combining information from the two score statistics Qˆpi and Qˆλ, several
general approaches for combing p-values can be employed, for example a min-p approach (Huang et al., 2014;
Won et al., 2009), or a Fisher’s method approach Fisher (1925). In this case we calculate the separate p-values
pˆpi, and pˆλ for pi and for λ, and obtain an estimate of their joint distribution via perturbation resampling
so that a size α test can be computed for the statistics pˆm = min(pˆpi, pˆλ), and pˆF = log(pˆpi) + log(pˆλ), as
described below. These approaches have the advantage of putting the two statistics Qˆpi and Qˆλ on the same
scale via p-value for combination. Alternatively, we may rescale Sˆpi and Sˆλ as σˆ−1pi Sˆpi and σˆ
−1
λ Sˆλ and then
construct Qˆpi,λ = n
∑
ι∈{pi,λ} σˆ
−2
ι Sˆ
>
ι Sˆι =
∑
ι∈{pi,λ} σˆ
−2
ι Qˆι, where σˆ2ι = trace(Σ̂ι,ι) and Σ̂ι,ι is the estimated
Σι,ι.
2.3. Resampling Methods. To approximate the null distribution of the test statistics in practice, we
employ a resampling method to approximate Σ as well as the joint distribution of pˆpiand pˆλunder H0.
Specifically we generate n independent samples V = {Vi}ni=1 sampled from some fixed distribution with
E[Vi] = 1, V ar[Vi] = 1, such as Vi ∼ Exponential(1). For a given set of weightsV(b) = {V (b)i }ni=1, we obtain
the perturbed score vectors Sˆ(b) = (Sˆ(b)>pi , Sˆ
(b)>
λ )
>, where
(2.6) Sˆ(b)ι = (
n∑
i=1
V
(b)
i )
−1
n∑
i=1
rˆ
(b)
ι,i Ψ(Gi)V
(b)
i , rˆ
(b)
ι,i ≡ rι(Yi,X>i β̂
(b)
0,pi,X
>
i β̂
(b)
0,λ),
and β̂
(b)
0 =
(
β̂
(b)
0,pi, β̂
(b)
0,λ
)
is obtained by fitting a weighted ZIP regression under the null using weights V(b).
It can be shown that, under suitable regularity conditions,
√
n
(
Sˆ(b) − Sˆ
)
|D D→MVN(0,Σ) (Parzen et al.,
1994; Kline and Santos, 2012). Hence, for some large number B of repetitions of the resampling procedure,
we use the empirical distribution
{
Qˆ
(b)
ι ≡ n(Sˆ(b)ι − Sˆι)>(Sˆ(b)ι − Sˆι)
}B
b=1
to approximate the asymptotic dis-
tribution of Qˆι. In order to calculate p-values with greater precision than 1/B we use Imhof’s method
(Imhof, 1961) to obtain the distribution of the quadratic form Qˆι, under the established multivariate nor-
mality on the half-statistic Sˆι, via the eigendecomposition of the empirical covariance of the resampling
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distribution
{
(Sˆ
(b)
ι − Sˆι)
}B
b=1
. This procedure is facilitated by the R package ‘CompQuadForm’ Duchesne
and de Micheaux (2010).
To calculate a p-value for the omnibus test, appropriately controlling type I error in the presence of cor-
relation between pˆpi and pˆλ, we take advantage of the same resampling procedure described above. For each
Sˆ
(b)
pi and Sˆ
(b)
λ , b = 1, ..., B, we use Imhof’s method to calculate a corresponding pˆ
(b)
pi and pˆ
(b)
λ . Define pˆm =
min(pˆpi, pˆλ). Then the null distribution of pˆm can be approximated using the resampling distribution{pˆ(b)m }Bb=1
where pˆ(b)m = min(pˆ
(b)
pi , pˆ
(b)
λ ). We can obtain a min-p p-value as pˆmin =
1
B
∑
b I
(
pˆ
(b)
m ≤ pˆm
)
. The null distri-
bution of pˆF is similarly obtained, leading to an alternative omnibus p-value: pˆFisher = 1B
∑
b I
(
pˆ
(b)
F ≤ pˆF
)
.
In our simulations we show that both pˆmin and pˆFisher have appropriate size under the null. Heuristically,
under the alternative we expect pˆFisher to perform worse than pˆmin with respect to power in cases when the
signal is either through pi or λ but not both, and to outperform pmin when an association signal appears
in both pi and λ. Indeed our simulations confirm pˆFisher modestly outperforms pˆmin when the association
signal is through both parameters.
3. Results
3.1. Simulations.
3.1.1. Simulation Setting. We generated data from a zero-inflated Poisson model of the form 2.1 with
logit(pii) = αpi + X>i βpi + G>Y iγpi, and log(λi) = αλ + X
>
i βλ + G
>
Y iγλ. We varied both the genetic data
distribution and parameter settings across five overall simulation scenarios, the first four of which examine
size of the test under the null. In setting 1), we fix the sample size at n = 1000 but considered simple cases
where X is either absent or is independent of G. In setting 2), we let X to be moderately correlated with G
and let the sample size n = 1000, 2000 and 4000. In setting 3), we varied the correlation strength between X
and G, up to a maximum pairwise correlation of approximately 0.9 to investigate the impact of correlation
on the results. In setting 4), we simulated data with overdispersion by including an unobserved covariate
associated with the outcome. This was to determine how robust our method is to this important deviation
from the assumptions of the specified model. In setting 5), we generated data under the alternative, where
the outcome was associated with (i) both pii and λi , (ii) only with pii , and (iii) only with λi , in order inves-
tigate how power depends on the source of the signal. Here, the covariates X were generated independent
of G.
Across all scenarios to obtain genetic marker data Gi we used HAPGEN2 (Su et al., 2011) to generate
haplotypes from 1000 genomes phase one data, CEU panel, using two representative SNP sets. First, from
the APOE gene, known to be associated with our neuritic plaque burden in our example, we used the 8
SNPs in the set {rs10119, rs429358, rs7412, 19-50106239, rs445925, rs483082, rs59325138, rs438811},
and second from the CD33 gene, we used the 22 SNPs in the set {rs273637, rs273638, rs273639, rs273640,
rs1399837, rs3826656, rs1710398, rs1697553, 19-56419774, rs2459141, 19-56420453, rs7245846, rs34813869,
rs1354106, rs35112940, rs10409348, rs273652, rs1697531, rs169275, rs273649, rs273648, rs273646}. In either
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case under the alternative, 3 SNPs GY i (in bold) were associated with the outcome under the true data
generation model. The APOE gene has a low-moderate LD across all selected SNPs while the CD33 gene
has two independent haploblocks with strong LD. We used these specific SNP sets to account for the effect
of differing linkage disequilibrium (LD) structures (correlation) and genotype dimension on the performance
of our method when applied to various genes.
In each scenario we compared our method to the multivariate Wald test from three models: the zero-
inflated poisson, the zero-inflated negative binomial, and a simple Poisson model using the robust Huber-
White (HW) variance. For each competing model except the single-parameter Poisson model, we performed
multivariate Wald tests on γ̂pi and γ̂λ separately, as well as the combined test of the vector concatenation
(γ̂>pi , γ̂
>
λ )
>. For each Wald test, because Poisson, ZIP, and ZINB models failed to achieve convergence with
maximum likelihood due to the collinearity in these SNP sets, in each round of our simulation we performed
an LD pruning on the matrix G, with SNPs chosen so that no pairwise correlation was above 0.99. For
APOE, this LD pruning resulted in no removal of SNPs, however for CD33, this reduced the number of
SNPs in the model from 22 to approximately 12, and potentially varied depending on the data.
To specify covariates, for those scenarios where Xi is independent of Gi, we set XInd,i = (X1i, X2i, X3i, X4i, X5i)>,
where each Xki is a complex linear combination of independent binomial and normal random variables, with
pairwise correlations that ranged from approximately 0.1 to 0.9. The complete specification is shown in the
Appendix. When Xi is dependent on Gi, we set Xi,Dep = ρXGAGY i + XInd,i, where the X : G association
is through a matrix A shown in the Appendix, and ρXG is a scalar correlation strength parameter chosen
to be 0.25, 0.5, or 1, representing a mild, moderate, or strong correlation, respectively. . When ρXG =0.25,
0.5 and 1, the maximal pairwise correlations in the X : G correlation matrix were approximately 0.23, 0.44
and 0.64 for APOE and 0.58, 0.84, and 0.92 for CD33 respectively.
For all settings, αpi = 1.5, αλ = 1.3, βpi = (0.75, 0.5, 0.25, 1.0, 1.0), βλ = (0.25, 0.5, 0.75, 1.0, 1.0). For
settings where GY i is associated with the outcome, for APOE, we set γpi = (0.066, 0.33, 0.66), and γλ =
(0.11, 0.055, 0.011), while for CD33, we set γpi = (0.036, 0.18, 0.36) , and γλ = (0.06, 0.03, 0.006). Depending
on the gene, the dimension of Gi was either p = 8 or p = 22, but in each case there were 3 SNPs GY i
associated with Yi under the alternative, while the rest were not included in the true association model.
For setting 4) in which the model is mis-specified due to overdispersion, the true data generating mecha-
nism is parameterized by logit(pii) = αpi+X>i βpi+G>Y iγpi, (as above), but log(λi) = αλ+X
>
i βλ+G
>
Y iγλ+ελ,i
where ελ,i ∼ Normal(0, 0.32).
All testing was performed using the linear kernel test statistic with Ψ(G) = G. In each scenario, the
nominal size of the type I error is α = .05. Unless otherwise stated, the simulated data had sample size
n = 1000.
3.1.2. Simulation Results. We first compare our proposed variance component (VC) tests of the individual
parameters pi and for λ described above (here denoted VCpi and VCλ) with the corresponding Wald tests
from the zero-inflated Poisson model and the zero-inflated negative binomial model (denoted Waldpi,ZIP ,
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Figure 3.1. Legend for following plots of simulation results.
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Figure 3.2. Empirical Sizes of different testing procedures for Setting 1) (a) withoutX;
and (b) withX.
Waldpi,ZINB , Waldλ,ZIP and Waldλ,ZINB). Additionally we compared six tests of the global null: three
methods of combining our tests on pi and λ, namely the min-p approach (VCmin), the Fisher’s method
approach (VCFisher), and the variance-standardized approach (VCstd) based on the statistic Qˆpi,λ proposed in
Section 2, along with the Wald test using the Huber-White robust variance from the Poisson model (HWPois)
and the Wald tests of combined pi and λ vector in the ZIP and ZINB settings (WaldZIP , WaldZINB).
3.1.3. Size of the tests under correct model specification. Settings 1) - 3) allow us to whether the size of the
test is maintained in finite sample under correct specification of the model but with varying configurations
for sample sizes and correlation structures. Results summarized in Figures 3.2, 3.3 and 3.4 suggest that type
I errors of all methods except for the HW procedure are well-controlled, with empirical sizes close to the
nominal α of 0.05 across all scenarios, under both the APOE and CD33 LD structures. The HW procedure
appears to yield inflated type I errors for a majority of the settings and is thus removed from subsequent
power comparisons. It is worth noting that the correlation between the covariates Xi and the tested genetic
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Figure 3.3. Empirical sizes of different testing procedures for Setting 2) when n =1000,
2000, and 4000.
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Figure 3.4. Empirical sizes of different testing procedures for Setting 3) when the corre-
lation between X and G is weak, moderate or strong.
markers Gi plays relatively little role in affecting type I error of our method unless levels of correlation are
quite high, e.g. where the maximal element of the X : G correlation matrix is above 0.8.
3.1.4. Effect of mis-specification (overdispersion) on size of tests. In this scenario we investigate the robust-
ness of different testing procedures in preserving type I errors in the presence of overdispersion and hence
model mis-specification. Specifically, as described above, we included a Normally distributed covariate in the
ZIP data generating model for λ that was not controlled for in the models we used to derive the tests. We
see in Figure 3.5 that the type I error of our VC test was relatively robust to overdispersion, but performance
was compromised in APOE with increased X : G correlation. As a comparison, the ZIP Wald test was badly
compromised in terms of type I error with the amount of overdispersion in this setting, resulting in a sizes
ranging from 0.4 to 0.9. Both the Wald test based on ZINB and our VC tests only have slight inflation of
type I error in the presence of mis-specification due to overdispersion.
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Figure 3.5. Empirical sizes of different testing procedures for Setting 4) with overdispersion
and weak, moderate or strong X : G correlation.
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Figure 3.6. Power of different testing procedures when G affects (a) both mixing propor-
tion and Poisson rate; (b) mixing proportion only; and (c) Poisson rate only.
3.1.5. Power. Figure 3.6 shows empirical power of different testing procedures when G is associated with
(a) both pi and λ; (b) pi only; and (c) λ only. We find that our method outperforms the competing methods
on power in most scenarios, especially with those where the true signal is through the mixing proportion pi
alone. There the APOE plots suggests that in some LD scenarios the power of our method can outperform
the competitors when the true signal is from pi, but underperform when the signal is from λ. The combined
test has comparable performance to competing methods in the lower-dimensional APOE case. However in
the higher dimensional CD33 scenario we find that the power of our method is consistently superior.
3.2. Data Application.
3.2.1. Data Set. The ROSMAP study is a longitudinal, epidemiologic clinical-pathologic cohort study fol-
lowing subjects who are free of cognitive impairment at baseline. It focuses on cognition, tested annually,
while also investigating correlated pathology in postmortem brain tissue analysis. Further details of the
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study can be found in Bennett et al. (Bennett et al., 2012). Genotype information was generated using the
Affymetrix GeneChip 6.0 genotype platform, as described in Chibnik et al. (2011). Genotyping in the original
study was limited to self-identified non-Hispanic Caucasians to reduce population heterogeneity. Remaining
population heterogeneity was controlled by using the first three eigenvectors of an eigendecomposition of
the genotypes. Genotypes were imputed using BEAGLE software, version 3.3.2 and 1000 Genomes Project
Consortium interim phase I haplotypes, 2010-2011 data freeze. Association analysis was performed using
the imputed genotype dosages.
Among 983 subjects who had died and had postmortem NP pathology measurements as well as imputed
genotypes as of 2015, we restricted to the 970 subjects for whom the covariate ‘packyears at baseline’, a
smoking status indicator, was recorded. We also include sex and age at death as covariates. The covariates
‘packyears at baseline’ and ‘age at death’ are included in the models as linear terms.
To illustrate the utility of our method we applied the test to several candidate genes, including ABCA7,
APOE, CD33, MAPT and PTPRD, which have previously been shown to be associated with the AD risk.
APOE on cytoband 19q13.32 (Zhong, 2017) is a well known gene previously reported to be associated with
Alzheimer’s risk (Lambert, 2013). The previously reported GWAS SNPs for APOE were rs429358, and
rs7412, which we used to obtain additional SNPs in LD. The additional genes we analyzed were ABCA7
(19p13.3 ; rs3752246, rs3764650), CD33 (19q13.41; rs3865444, rs3826656), MAPT (17q21.31; rs1800547,
rs3785883, rs8070723) and PTPRD (9p23; rs560380, rs3764650). These genes and SNPs have also been found
to be associated with Alzheimer’s (Lambert, 2013; Giri et al., 2016). The previously reported GWAS SNPs
for CD33 were rs3865444, rs3826656. To select a SNP set for analysis we started with all BEAGLE imputed
SNPs lying within the boundaries of the gene along with those ±10000 bp upstream and downstream. We
restricted to those SNPs which matched the candidate gene on the flag ‘ensembl_gene_id’ in the Ensembl.org
GRCh38.11 data. We further restricted to SNPs with a variance equivalent to an MAF of 0.01 or above. We
also restricted to SNPs that were in LD, with correlation ranging from 0.4 to 0.95, with SNPs previously
reported to be significantly associated with the AD case-control phenotype in GWAS. These restrictions
yields 8 SNPs for APOE and 22 for CD33.
The phenotype outcome we analyze is a total count measure of neuritic plaques (NP), taken from five
sites: hippocampus CA1, entorhinal cortex, inferior parietal cortex, midfrontal cortex, and midtemporal
cortex. The site-specific counts are recorded by a technician who observes tissue pathology slides from each
site, and are then summed to obtain a total count. The total count shows evidence of both zero-inflation
and overdispersion (see figure 3.7).
3.2.2. Data Analysis Results. In Table 1, we present p-values for these genes obtained based on our proposed
VC test as well as the ZINB Wald test. Other competing tests were excluded from this analysis due to their
susceptibility to inflated type I error. We take α = 0.05 as the nominal size.
Looking at the results from our proposed method, significant p-values for APOE are consistent with past
studies which have shown it to be strongly related to Alzheimers risk. We note that the p-value associated
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Figure 3.7. Histogram of NP outcome
pi:
VC
pi:
ZINB Wald
λ:
VC
λ:
ZINB Wald
pi&λ:
VC std.
pi&λ:
ZINB
ABCA7 2.1E-01 2.1E-02 1.9E-01 6.6E-01 1.8E-01 1.1E-01
APOE 1.1E-08 2.0E-06 1.6E-06 1.4E-08 5.8E-12 4.4E-13
CD33 3.5E-01 6.7E-01 9.9E-01 3.9E-01 7.4E-01 5.8E-01
MAPT 7.7E-01 8.5E-01 4.1E-01 8.6E-01 6.7E-01 9.4E-01
PTPRD 4.0E-01 7.6E-01 3.0E-04 2.7E-01 1.6E-03 5.2E-01
Table 1. Data analysis results: p-values of selected genes in ROSMAP data
with λ is more extreme than that for pi. Thus the evidence that APOE is associated with total count of
neuritic plaques appears to be stronger than the evidence APOE is associated with the presence or absence
of plaques. Note however, that at least part of this discrepancy can be accounted by relative power in the
tests for pi and λ, which may be affected both by effect size and by different statistical considerations for each
parameter. For example it is well known that in tests of binary regression, power is a function of pi, with
lower power as pi approaches 0 or 1, and the same pattern is expected to hold here. By contrast, a strong
association signal in pi but not λ might suggest that the biological mechanism is ‘all-or-nothing’, meaning
it may prevent or allow formation of neuritic plaques, but does not affect the rate of plaque formation if it
occurs. However, we caution against making any conclusions of this sort solely based on p-values.
To illustrate the breakdown of genetic effects within a SNP set, we performed ZINB regression for the NP
outcome to estimate genetic effects through pi and λ for each SNP in APOE, using a single-SNP marginal
model approach (but still controlling for the above-mentioned covariates). We also computed the effect
estimate for the regression against the APOE ε4 allele count, to compare results for individual SNPs with
those for this well-known haplotype. In Figure 3.8 we report the maximum likelihood estimates of genetic
effects γpi and γλ, along with their standard errors, and the corresponding VCpi or VCλ p-value. Results for
previously reported GWAS snps rs429358, and rs7412 show a strong signal in our analysis in both pi and λ.
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Figure 3.8. Plot of APOE SNP and APOE-ε4 haplotype effects from marginal models
Farebrother’s method (Farebrother, 1984), implemented in the R statistical software package ‘CompQuad-
Form’, was used to calculate the the distribution of Qˆι in both the marginal and the gene-level data appli-
cation in order to obtain additional precision for the p-values. Nevertheless, the p-value was calculated as 0
for the test of pi for the APOE ε4 allele .
4. Discussion
We have derived novel VC tests that can efficiently detect the association between a set of genetic markers
and a zero-inflated count outcome. We have shown the test to adequately control type I error in many
simulation scenarios and have shown our method to obtain superior power to competing tests especially with
large or sparse sets of markers with certain LD structures. Additionally we have seen that the proposed
method has feasible application to genomic data from an Alzheimer’s data study. The proposed VC testing
procedures appear to adequately control type I error in all of the correctly specified simulation settings we
investigated. The test is also not sensitive to the presence of model mis-specification due to overdispersion,
which is of practical importance. This is in part due to the use of perturbation resampling for ascertaining
asymptotic distribution. Even under model mis-specification, provided that X is independent of G, our
proposed procedure can be shown to preserve the type I error.
The standard GWAS remains one that considers testing individual SNPs separately. It is possible to
take this marginal approach using our method. However, we believe that the potential to combine SNP
effects at the gene level is likely to increase power in many circumstances. The linear model proposed in this
paper to test the association of individual genes with a ZIP phenotype is probably adequate for a proportion
of such associations, in particular we detect a signal in the APOE gene, despite not explicitly coding the
APOE ε2, ε3, and ε4 haplotypes but instead using additive SNP effects. However, if it is important to
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capture interactions or other complex SNP effects, our method easily admits a generalization which makes
this possible.
With proper choices of Ψ(·), our proposed procedure corresponds to a kernel machine score test that can
be used to detect non-linear effects. Specifically, suppose hι(G) ∈ HK withHK = span{ψ`(G·), ` = 1, ...,J }
being a reproducible kernel space generated by a given positive definite kernel function K(·, ·) (Cristianini
and Shawe-Taylor, 2000). Then letting Ψ(·) = [ψ`(·), ..., ψJ (·)]> leads to a score test of the form rˆ>ι Krˆι,
where rˆι = (rˆι,1, ..., rˆι,n)>and K = [K(Gi,Gj)]n×n is the observed kernel matrix. Intuitively K(·, ·) defines
a measure of genetic similarity between different subjects’ genotypes. Moreover, this transformation projects
the original genotype information via a nonlinear transformation to a larger function space which can be
incorporated into the model linearly. Different choices of kernel (see Wu et al., 2010) allow different bases
for the non-parametric function modeling the association between the ZIP outcome and the q markers in the
SNP set, in turn allowing for power to test complex relationships and interactions.
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Appendix 1: asymptotic distribution
We next outline the key steps for deriving the asymptotic distribution for
√
nSˆ ≡ √n(Sˆ>pi , Sˆ>λ )> un-
der H0. To this end, we write Sˆι = S˜ι(β̂0) and S¯ι = S˜ι(β0) = n−1
∑
rι,iΨ(Gi), where S˜ι(β) =
n−1
∑
rι(Yi,X
>
i βpi,X
>
i βλ)Ψ(Gi), and rι,i = rι(Yi,X
>
i β0,pi,X
>
i β0,λ) First, by a standard law of large num-
bers and properties of the maximum likelihood estimator, we have β̂0 → β0 in probability and
√
n(β̂0−β0) =
n−1/2
∑n
i=1{(I−1pi Upi,i)>, (I−1λ Uλ,i)>}> + op(1) which converges in distribution to a zero-mean multivari-
ate normal. On the other hand, it follows from a uniform law of large numbers (Pollard, 1990) that
S˜ι(β) − sι(β) → 0 in probability uniformly in β, where sι(β) = E
{
rι(Yi,X
>
i βpi,X
>
i βλ)Gi
}
. Therefore,
|Sˆι| = |Sˆι − sι(β0)| ≤ supβ |S˜ι(β) − sι(β)| + |sι(β̂0) − sι(β0)| → 0 in probability. The first equality is due
to the fact that sι(β0) = 0, which can be verified as follows:
E [rpi,i] ≡ E
[
IYi=0
P (Yi > 0)
P (Yi = 0)
(1− pi0,i)− IYi>0(1− pi0,i)
]
= P (Yi > 0)(1− pi0,i)− P (Yi > 0)(1− pi0,i) = 0
E [rλ,i] ≡ E
[
IYi=0
λ0,ipi0,iexp(−λ0,i)
P (Yi = 0)
− IYi>0(Yi − λ0,i)
]
=
(
λ0,ipi0,iexp(−λ0,i)
P (Yi = 0)
)
P (Yi = 0)− (E[YiIYi>0]− λ0,iE[IYi>0])
= λ0,ipi0,ie
−λ0,i − λ0,ipi0,i + λ0,ipi0,i(1− e−λ0,i) = 0.
To establish the asymptotic distribution for
√
nSˆ, we first note that by the functional central limit the-
orem (Pollard, 1990),
√
n{S˜(β) − s(β)} converges weakly to a zero-mean Gaussian process and thus is
equicontinuous in β. This, together with a Taylor series expansion, implies that
√
nSˆι ≡
√
n
{
S˜ι(β̂0)− S˜ι(β0)
}
+
√
nS¯ι
=
√
n(ρι,pi, ρι,λ)(β̂0 − β0) +
√
nS¯ι
= n−1/2
∑
i
{
ρι,piI−1pi Upi,i + ρι,λI
−1
λ Uλ,i + rι,iΨ(Gi)
}
+ op(1).
It then follows from a central limit theorem that
√
nSˆ converges in distribution to a multivariate normal
distribution MVN(0,Σ).
One can show that if S ∼MVN(0,Σ), then S>S has an asymptotic distribution as a linear combination
of independent χ21 random variables. For completeness, we sketch the argument here. First note S>S =(
S>Σ−
1
2
)
Σ
(
Σ−
1
2 S
)
so we can write S>S = U>ΣU where U = Σ−
1
2 S ∼ MVN(0, Ip×p). Then find the
spectral decomposition Σ = A>ΛA, where Λ is diagonal and A>A = AA> = Ip×p. Hence for V = AU,
V ar[V] = AV ar[U]A> = AA> = I. So V is multivariate normal with identity covariance, and the kth
element of V, Vk is standard normal. So we have S>S = V>ΛV =
∑
k λkVk · Vk =
∑
k λkχ
2
1.
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Appendix 2: simulation settings
Specification of Xi = (X1i, X2i, X3i, X4i, X5i)>:
X1i ∼ binomial(k = 2, p = 0.5)
W2i ∼ binomial(2, 0.5), Z2i ∼ normal(µ = 0, σ2 = .25)
X2i = 0.5(W2) + Z2
Z3i ∼ normal(µ = 0, σ2 = .25))
X3i ∼ 0.1X1iX2i + Z3i
W4i ∼ binomial(2, 0.4), Z4i ∼ normal(µ = 0, σ2 = .25)
X4i = 0.1(W4i)− 0.2(X2i) + 0.2(X3i) + Z4i
W5i ∼ 0.5(binomial(n, 2, 0.4), Z5i ∼ normal(µ = 0, σ2 = .25)
X5 = 0.5(W5i) + 0.15(X2i) + 0.2(X3i) + Z5i
Genotype-Covariate Dependence Matrix:
A =

0.08 0.5 0.0 0.5 0.8
0.09 0.4 0.1 0.0 0.0
0.0 0.0 0.3 0.6 0.9

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Appendix 3: table of results
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Table 1: Table of p-value results. See text for detailed descriptions of simulation scenarios.
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Supplement 1: gene SNP sets
Gene sets for simulations and data analysis:
ABCA7 [46 SNPs]
rs930232, rs930231, rs3848640, rs3764642, rs4147904, rs3764645, rs4622634, rs4147909, rs3752237, rs4147912,
rs4147914, rs7408475, rs12151021, rs3764651, rs3764652, rs3829687, rs3752242, rs3752243, rs3745842, rs11671895,
rs881768, rs3752246, rs2279796, rs2868065, rs10411696, rs11671157, rs4147922, rs4147923, rs1968456, rs4147924,
rs558820627, rs4807499, rs4147930, rs4147931, rs4147932, rs1609436, rs4147934, rs4147936, rs2242437, rs2242436,
rs4147938, rs905149, rs12981369, rs1610096, rs3764653, rs1801284
APOE [8 SNPs]
rs10119, rs429358, rs7412, rs72654473, rs445925, rs483082, rs59325138, rs438811
CD33 [22 SNPs]
rs273637, rs273638, rs273639, rs273640, rs1399837, rs3826656, rs1710398, rs1697553, rs3865444, rs2459141,
rs2455069, rs7245846, rs34813869, rs1354106, rs35112940, rs10409348, rs273652, rs1697531, rs169275, rs273649,
rs273648, rs273646
MAPT [62 SNPs]
rs7210728, rs4792891, rs9303523, rs28646281, rs1560312, rs3785879, rs9915721, rs9899833, rs3785880,
rs8080903, rs1560313, rs9904290, rs1001945, rs8078967, rs2435205, rs242557, rs242562, rs878918, rs242554,
rs2664006, rs9896485, rs10514889, rs1800547, rs754593, rs6503453, rs713522, rs2471737, rs2435200, rs2435201,
rs8067056, rs12946693, rs56087321, rs41543317, rs62062273, rs916896, rs7521, rs7220988, rs8070723, rs3744456,
rs66660193, rs71375325, rs3785883, rs2435206, rs2435207, rs7209707, rs63750072, rs2435209, rs2435210,
rs2435211, rs11568305, rs7216893, rs2435202, rs73317025, rs73317026, rs11079728, rs41543512, rs60969130,
rs66499584, rs67676322, rs16940797, rs11652638, rs1078997
PTPRD [62 SNPs]
rs408960, rs324512, rs324513, rs324514, rs192973, rs635725, rs493588, rs634921, rs634098, rs580780,
rs324481, rs324482, rs324483, rs324484, rs324485, rs182720, rs324486, rs324487, rs324488, rs324474, rs324475,
rs324476, rs324478, rs324479, rs324480, rs526677, rs526675, rs324473, rs324472, rs324470, rs324469, rs324468,
rs484454, rs674362, rs369166, rs523872, rs500091, rs2784543, rs2777489, rs3004230, rs828405, rs448616,
rs557369, rs324465, rs172863, rs324466, rs324467, rs472324, rs324543, rs324542, rs10759040, rs324546,
rs324545, rs324544, rs560380, rs324541, rs324540, rs1373806, rs324548, rs17666445, rs2007138, rs436929
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8 imputed SNPs in APOE:
{rs10119, rs429358, rs7412, 19-50106239, rs445925, rs483082, rs59325138, rs438811}
(3 SNPs, GY i (in bold), were associated with the outcome in the simulated data.)
APOE: 8 SNPs. Pairwise LD (R2)
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Figure 4.1. LD structure of selected APOE SNPs: HAPGEN Data
Pairwise LD in r^2
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Figure 4.2. LD structure of selected APOE SNPs: ROSMAP Data
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22 imputed SNPs in CD33:
{rs273637, rs273638, rs273639, rs273640, rs1399837, rs3826656, rs1710398, rs1697553, 19-56419774,
rs2459141, 19-56420453, rs7245846, rs34813869, rs1354106, rs35112940, rs10409348, rs273652, rs1697531,
rs169275, rs273649, rs273648, rs273646}
(3 SNPs, GY i (in bold), were associated with the outcome in the simulated data.)
CD33: 22 SNPs. Pairwise LD (R2)
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Figure 4.3. LD structure of selected CD33: HAPGEN data
CD33: 22 SNPs. Pairwise LD (R2)
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Figure 4.4. LD structure of selected CD33 SNPs: ROSMAP Data
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